Cargando…
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
Cisplatin (CDDP) is commonly used to treat a multitude of tumors including sarcomas, ovarian and cervical cancers. Despite recent investigations allowed to improve chemotherapy effectiveness, the molecular mechanisms underlying the development of CDDP resistance remain a major goal in cancer researc...
Autores principales: | Vianello, Caterina, Cocetta, Veronica, Catanzaro, Daniela, Dorn, Gerald W, De Milito, Angelo, Rizzolio, Flavio, Canzonieri, Vincenzo, Cecchin, Erika, Roncato, Rossana, Toffoli, Giuseppe, Quagliariello, Vincenzo, Di Mauro, Annabella, Losito, Simona, Maurea, Nicola, Scaffa, Cono, Sales, Gabriele, Scorrano, Luca, Giacomello, Marta, Montopoli, Monica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033831/ https://www.ncbi.nlm.nih.gov/pubmed/35459212 http://dx.doi.org/10.1038/s41419-022-04741-9 |
Ejemplares similares
-
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
por: Vianello, Caterina, et al.
Publicado: (2022) -
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
por: Vianello, Caterina, et al.
Publicado: (2023) -
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
por: Vianello, Caterina, et al.
Publicado: (2023) -
Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives
por: Cocetta, Veronica, et al.
Publicado: (2021) -
Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth
por: Zamberlan, Margherita, et al.
Publicado: (2022)